
Supplementary Figure 1: Gating strategy for Natural Killer(NK) cells(a) and monocytes(b). NK cells were gated as singlets, CD45^{pos}, CD14^{neg}, FSC-SSC appropriate for lymphocytes, CD3^{neg}, CD16/CD56^{pos} cells and then gated further as CD56^{bright}, CD56^{dim} or CD56^{neg} NK cells. Monocytes were similarly gates as singlet, CD45^{intermediate}/SSC appropriate for monocytes, CD3^{neg}, CD14/CD16^{pos} cells and then gated further as classical(CD14^{hi}CD16^{neg}), intermediate(CD14^{hi}16^{lo}) or non-classical(CD14^{lo}CD16^{hi}) monocytes. Gating of CXCR3, CX3CR1 or CD69 expression was performed using fluorescenceminus-one gates(FMO) to set lower thresholds for gating.

Supplementary Figure 2: Four weeks of cART therapy did not affect CXCR3 expression on CD56^{bright}(a) or CD56^{dim}(b) NK cells, but reduced the proportions of CD69^{pos} activated NK cells in both CD56^{bright}(c) and CD56^{dim}(d) NK cell fractions. Week 0 refers to start of cART and Week 4 refers to sampling after 4 weeks of cART. Results are expressed as the percentage of total monocytes. Medians (horizontal lines) and interquartile ranges (whiskers) are shown in each graph. Measurements in blood denoted by black squares (a) and in CSF denoted by grey circles(b).


Supplementary Figure 3: CX3CR1 expression differed by NK cell subset(CD56^{bright}, CD56^{dim}) and compartment. In blood, at enrolment the proportion of NK cells expressing CX3CR1 was similar between CD56^{bright} and CD56^{dim} NK cells, but in CSF, a larger proportion of CD56^{bright} NK cells expressed CX3CR1 compared with CD56^{dim} NK cells(a). The proportion of CD56^{bright} NK cells expressing CX3CR1 was significantly higher in blood at enrolment and after completion of anti-fungal therapy induction(b). Amongst CD56^{dim} NK cells, no differences in CX3CR1 expression between CSF and blood were noted at enrolment or after completion of anti-fungal therapy.(c). Medians (horizontal lines) and interquartile ranges (whiskers) are shown in each graph.

Supplementary Figure 1


Α



В



Supplementary Figure 2



Supplementary Figure 3

